Case Reports in Gastroenterology, published by KARGER, is a dedicated open-access journal that has been providing an invaluable platform for the dissemination of important clinical findings and innovative treatments in the field of gastroenterology since its establishment. With its E-ISSN of 1662-0631, this journal fosters academic exchange and research development by publishing case reports that highlight novel insights and practical applications in gastrointestinal medicine. The journal is significant within its category, holding a Q3 quartile ranking as of 2023 in gastroenterology, and is positioned at rank #121 out of 167 in Scopus’ classification for gastroenterology medicine. With a convergence period from 2010 to 2024, researchers, professionals, and students are encouraged to contribute and access high-quality, peer-reviewed content. Alongside its commitment to open access, which enhances visibility and accessibility to vital research, Case Reports in Gastroenterology remains a respected resource for those seeking to expand their knowledge and engage with contemporary developments in the gastroenterological community.

The American Journal of Case Reports, published by INT SCIENTIFIC INFORMATION, INC since 2008, serves as a crucial platform in the field of Medicine, specifically focusing on clinical cases that enhance medical knowledge and expertise. With an impact factor that reflects its quality and relevance, this journal ranks in the Q3 quartile of its category and holds a notable position at Rank #259 out of 636 in the Scopus Medicine rankings, placing it within the 59th percentile among its peers. Intended for researchers, healthcare professionals, and students, the American Journal of Case Reports advocates for the sharing of distinctive case studies, thus fostering a deeper understanding of clinical practice and patient care across a spectrum of medical disciplines. As an open access journal, it ensures widespread dissemination of vital case reports, opening avenues for global collaboration and knowledge exchange, ultimately enhancing evidence-based practice in medicine.

Internal Medicine is a distinguished peer-reviewed journal published by the Japan Society of Internal Medicine, focusing on the nuanced field of internal medicine. Since its inception in 1974 and with a commitment to advancing medical knowledge, the journal has evolved remarkably, aiming to disseminate high-quality research that contributes to the understanding and treatment of internal diseases. Operating from Tokyo, Japan, it provides an intellectual platform for researchers and clinicians to publish original articles, reviews, and case studies that address various aspects of internal medicine. The journal currently holds a ranking in the Q3 quartile for both Internal Medicine and miscellaneous Medicine categories as of 2023, signifying its growing influence in the medical community. Although not an open-access journal, it remains accessible to a wide audience through institutional subscriptions, enhancing its reach among professionals and students alike. With its commitment to excellence, Internal Medicine serves as an essential resource for those seeking the latest developments and research within this vital medical field.

The World Journal of Clinical Cases is a premier publication dedicated to the dissemination of high-quality clinical research and case reports that contribute to enhancing clinical practice and patient care. Established by BAISHIDENG PUBLISHING GROUP INC, this journal has established itself as a significant resource in the field of medicine, achieving a Q3 ranking in the miscellaneous category as of 2021 and maintaining a competitive position with a Scopus rank of #443/826. With coverage from 2018 to 2023, the journal focuses on diverse aspects of general medicine, promoting innovative research and clinical insights. Although it is not listed as open access, researchers and practitioners can benefit from its focused scope, aiding in knowledge advancement and fostering collaborative efforts in the medical community. The journal's commitment to quality and integrity makes it an essential platform for professionals seeking to stay informed about the latest clinical developments.

Acta Oto-Laryngologica Case Reports, published by Taylor & Francis Ltd, is an esteemed open-access journal dedicated to the dissemination of high-quality case reports in the field of otolaryngology. Since its inception in 2016, this journal has been a vital platform for researchers and clinicians to share unique clinical insights and advancements related to ear, nose, and throat disorders. With an ISSN of 2377-2484, it provides unparalleled access to the latest findings, facilitating collaboration and innovation among professionals in otolaryngology. The journal's commitment to open-access publishing ensures that critical research is freely available to a global audience, enhancing the visibility and impact of its contributors' work. Researchers, practitioners, and students in the medical field will find valuable resources and case studies that not only contribute to professional development but also address current challenges in patient care.

Case Reports in Oncology is a peer-reviewed journal published by KARGER, dedicated to the dissemination of high-quality case studies and clinical reports in the field of oncology. Since its transition to Open Access in 2008, this Swiss-based journal has aimed to broaden the accessibility of key findings to a global audience of researchers, healthcare professionals, and students. The journal is positioned in the Q3 quartile for oncology, indicating its valuable contribution to the field, while also holding a Scopus rank of 294 out of 404 in Medicine, with a percentile of 27%. However, its open access model ensures that even those outside of traditional academic institutions can engage with critical advancements and novel insights from the oncology community. With a publication span extending from 2010 to 2024, Case Reports in Oncology serves as a crucial platform for sharing unique clinical experiences and innovative treatment strategies, ultimately enriching the practice and study of oncology.

Rare Tumors, published by SAGE Publications Ltd, is a premier open-access journal dedicated to advancing the understanding and research of rare neoplasms. With the ISSN 2036-3605 and E-ISSN 2036-3613, this journal provides a vital platform for sharing innovative research findings and clinical insights since its inception in 2009. Situated in Italy, Rare Tumors has a converged publication timeline from 2010 to 2024 and aims to foster a supportive community for researchers and professionals in the oncology and histology fields. It has achieved a notable Q3 ranking in Oncology and Q4 in Histology as of 2023, reflecting its crucial role in bridging the knowledge gap in these specialized areas. Despite its relatively humble Scopus ranks, the journal's open-access model ensures that vital information reaches a broad audience, including those in academia, clinical practice, and beyond. It aspires to not only document rare tumor cases but also stimulate dialogue on their diagnosis, treatment, and management strategies, making it an indispensable resource for anyone dedicated to tackling the challenges posed by rare tumors.

CHEMOTHERAPY, published by KARGER, is a premier academic journal established in 1960, dedicated to disseminating cutting-edge research and advancements in the fields of drug discovery, infectious diseases, oncology, and pharmacology. With an impressive Scopus ranking placing it in the Q2 category for major disciplines such as Drug Discovery and Infectious Diseases, this journal provides an invaluable platform for researchers and professionals aiming to explore new therapeutic approaches and methodologies. Located in the heart of Switzerland, its publications are a key resource for anyone looking to stay informed about the latest developments and trends in the pharmacological sciences. Researchers can benefit from its diverse scope while contributing to a growing body of knowledge that emphasizes the importance of effective chemotherapeutic strategies in modern medicine. Despite not being an Open Access journal, CHEMOTHERAPY remains committed to maintaining a rigorous peer-review process, ensuring the highest quality of published work.

Molecular and Clinical Oncology is a dynamic journal published by SPANDIDOS PUBL LTD, aimed at advancing the understanding of cancer biology and treatment modalities. With an ISSN of 2049-9450 and an E-ISSN of 2049-9469, the journal serves as a critical platform for researchers and clinicians dedicated to uncovering novel insights in molecular oncology and enhancing clinical practices. As a testament to its growing influence, the journal has achieved a Q3 ranking in Oncology and a Q4 ranking in Cancer Research for the year 2023, reflecting its commitment to publishing high-quality research. Although currently not an Open Access publication, the journal offers crucial subscription options, ensuring comprehensive access to groundbreaking studies and innovations in the field. With converged years spanning 2018 to 2024, the journal is set to continue enriching the academic community with its valuable contributions, ultimately empowering researchers, professionals, and students engaged in the fight against cancer.

Chinese Clinical Oncology is a distinguished journal dedicated to advancing the field of oncology and clinical research, published by AME Publishing Company. Since its inception in 2012, this journal has established its significance within the academic community, boasting an impactful presence as evidenced by its 2023 Scopus rankings, where it is positioned in the 47th percentile in the field of oncology. This open access journal features a diverse range of research, reviews, and clinical studies that aim to bridge the gap between experimental and clinical oncology, making it an invaluable resource for researchers, medical professionals, and students alike. The journal is based in Hong Kong and is committed to publishing studies that contribute to the understanding and treatment of cancer, with a strong focus on innovative methodologies and emerging therapies. With a current categorization of Q2 in Medicine and Q3 in Oncology, Chinese Clinical Oncology offers a robust platform for scholarly communication and is pivotal for those involved in cancer research and treatment.